CXCL2 Protein (AA 39-107)

Catalog No. ABIN2666640

Recombinant CXCL2 protein expressed in Escherichia coli (E. coli).

Quick Overview for CXCL2 Protein (AA 39-107) (ABIN2666640)

Target: CXCL2 (Chemokine (C-X-C Motif) Ligand 2 (CXCL2))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: Escherichia coli (E. coli)

Application: Intracellular Flow Cytometry (ICFC)

Purity: > 98 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 39-107

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: Bioactivity was measured by its property to chemoattract human neutrophils in a dose dependent manner.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored from -20 °C to -70 °C. Stock solutions can also be prepared at 50-100 μg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2-1 % BSA or HSA and stored in working aliquots at -20 °C to -70 °C.

Buffer: 0.22 μm filtered protein solution is in PBS.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for six months, or at -70°C for one year.

Target Details

Target: CXCL2 (Chemokine (C-X-C Motif) Ligand 2 (CXCL2))

Alternative Name: CXCL2

Background: CXCL2 is an ELR CXC chemokine, and it is structurally and functionally related to GRO1 (CXCL1), GRO3 (CXCL3), and interleukin-8 (CXCL8). CXCL2 binds to the CXCR2 receptor, this receptor is shared with other ELR CXC chemokines (CXCL1, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8). CXCL2 is highly expressed in esophageal squamous cell carcinoma (ESCC), and it has been detected in serum of patients with this disease. Also, CXCL1, CXCL2 and CXCL3 have been showed to be highly expressed in patients with malignant melanoma. In addition, CXCL2 and CXCL1 are upregulated in the central nervous system in multiple sclerosis (MS) and in the animal model of experimental autoimmune encephalomyelitis (EAE). In EAE, it has been shown that transfer of encephalitogenic CD4+ Th17 cells induce CXCL1 and CXCL2 transcription in the spinal cords of naive, syngeneic recipients. IL-17 is a potent inducer of ELR+ CXC chemokines in MS and EAE. In fact, it has been showed that CXCL1 and CXCL1 are upregulated in the preclinical and clinical stages of EAE.

Molecular Weight: The 69 amino acid recombinant protein has a predicted molecular mass of approximately 7.5 kDa. The DTT-reduced protein migrates at approximately 10.5 kDa, and the non-reduced protein migrates at approximately 12.5 kDa by SDS-PAGE. The N-terminal amino aci

Pathways: Cellular Response to Molecule of Bacterial Origin